BioNexus Gene Lab Corp Files 8-K

TL;DR

BioNexus Gene Lab Corp filed an 8-K, expect updates soon.

AI Summary

BioNexus Gene Lab Corp. filed an 8-K on August 28, 2024, reporting events as of August 27, 2024. The filing primarily concerns Regulation FD Disclosure and includes Financial Statements and Exhibits. The company, incorporated in Wyoming, is based in Kuala Lumpur.

Why It Matters

This 8-K filing indicates that BioNexus Gene Lab Corp. is providing updates and disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — This filing is a routine disclosure and does not appear to contain immediate negative or positive news.

Key Numbers

• 001-41750 — SEC File Number (Identifies the company's filing with the SEC)
• 35-2604830 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• BioNexus Gene Lab Corp. (company) — Registrant
• August 27, 2024 (date) — Date of earliest event reported
• August 28, 2024 (date) — Date of report
• Wyoming (jurisdiction) — State of incorporation
• Kuala Lumpur (location) — Principal Executive Offices location

FAQ

Filing Documents

• bglc_8k.htm (8-K) — 26KB
• bglc_ex991.htm (EX-99.1) — 5KB
• 0001477932-24-005339.txt ( ) — 158KB
• bglc-20240827.xsd (EX-101.SCH) — 6KB
• bglc-20240827_lab.xml (EX-101.LAB) — 15KB
• bglc-20240827_cal.xml (EX-101.CAL) — 1KB
• bglc-20240827_pre.xml (EX-101.PRE) — 9KB
• bglc-20240827_def.xml (EX-101.DEF) — 2KB
• bglc_8k_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On August 27, 2024, BioNexus Gene Lab Corp. (the "Company") issued a press release announcing the successful co-investment by the Malaysian Ministry of Finance, through the Securities Commission Malaysia under its Malaysia Co-Investment Fund (MyCIF), into Ascension Innovation Sdn Bhd ("AISB"). This co-investment, alongside the Company's recent RM 1 million investment in AISB, underscores significant confidence from the Securities Commission in AISB's innovative technology and its potential to revolutionize healthcare through sustainable practices. It brings the total investment funding in this round to RM 1.7m (approx. USD 390k). The MyCIF co-investment, of which AISB is the first recipient, is part of the Environmental & Social Impact (ESI) scheme, which aims to support micro, small, and medium enterprises (MSMEs) with impactful solutions in obtaining funding through alternative channels. The co-investment will assist AISB in advancing its AI-driven healthcare solutions and contribute to the "One Patient, One Record" initiative under Malaysia's National Electronic Medical Records (EMR) Plan, aiming to modernize the nation's healthcare infrastructure. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit Description 99.1 Press Release Dated August 27, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioNexus Gene Lab Corp. Date: August 28, 2024 By: /s/ Su-Leng Tan Lee Name: Su-Leng Tan Lee Title: Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR